Tesamorelin is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Tesamorelin is being researched for fat loss applications. Activates GHRH receptors on anterior pituitary somatotrophs via cAMP-PKA cascade. Elevated GH drives hepatic IGF-1 production, reducing visceral adiposity through enhanced lipolysis and reduced trunca. Common dosages for this use range from 2 mg daily once daily.
Can Tesamorelin Help With Fat Loss?
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is being researched for fat loss applications based on its mechanism as a GHRH analog, growth hormone secretagogue.
Activates GHRH receptors on anterior pituitary somatotrophs via cAMP-PKA cascade. Elevated GH drives hepatic IGF-1 production, reducing visceral adiposity through enhanced lipolysis and reduced truncal fat distribution without altering systemic glucose homeostasis.
What Does the Research Show for Tesamorelin and Fat Loss?
Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025.
The relevance to fat loss specifically comes from Tesamorelin's effects on visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
What Protocol Is Used for Fat Loss?
For fat loss applications, the standard Tesamorelin protocol is 2 mg daily administered once daily via subcutaneous injection for ongoing maintenance; demonstrated benefit to 12+ months.
Some researchers adjust dosing based on the specific fat loss application — see our Tesamorelin dosage guide for full protocol details.
Can Stacking Improve Fat Loss Results?
Combines with insulin-sensitizing agents for enhanced metabolic restoration. Off-label stacking with testosterone in HIV patients addresses complementary pathways.
What Side Effects Apply to Fat Loss Use?
Well-tolerated. Injection site reactions most common. Transient flushing, headache, dizziness possible early on. No significant metabolic derangements.
Side effects are generally consistent regardless of the specific application. See our Tesamorelin side effects guide for details.
Calculate Your Tesamorelin Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Tesamorelin.
Open Calculator →Bottom Line: Tesamorelin for Fat Loss
Tesamorelin shows preliminary research potential for fat loss. Standard protocols (2 mg daily, once daily, ongoing maintenance; demonstrated benefit to 12+ months) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
Tesamorelin: The FDA-Approved GHRH Analog
Related Reading
- Tesamorelin Dosage Guide
- Tesamorelin Benefits
- Tesamorelin Side Effects
- Tesamorelin Stacking Guide
- Tesamorelin Cycle Guide
- Tesamorelin Research
Research-Grade Sourcing
If you're going to research Tesamorelin, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue. Synthetic 44 amino acid GHRH analog with enhanced metabolic stability and DPP-4 protease resistance. It is researched for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
What is the recommended Tesamorelin dosage?
Common dosages: 2 mg daily administered once daily via subcutaneous injection. Cycle length: ongoing maintenance; demonstrated benefit to 12+ months. Half-life: 26-38 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of Tesamorelin?
Well-tolerated. Injection site reactions most common. Transient flushing, headache, dizziness possible early on. No significant metabolic derangements.
Is Tesamorelin safe?
Tesamorelin has shown a favorable safety profile in research. FDA-approved (2010) for HIV-associated lipodystrophy. Prescription medication. All research should follow appropriate safety protocols.